[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,40,62,82,107,147,184,209,230,266,291],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100604803","phase-2-a-study-of-dzd8586-combination-in-cllsll-tai-shan10-100604803",false,"NCT07154264","A Study of DZD8586 Combination in CLL\u002FSLL (TAI-SHAN10)","A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL\u002FSLL)","Inclusion Criteria:\n\n1. Male and female ≥ 18 years of age.\n2. ECOG performance status 0-2, and life expectancy ≥ 6 months.\n3. Confirmed newly diagnosis or treatment naïve CLL\u002FSLL with indication for treatment.\n4. Patients with SLL must have at least one measurable lesion.\n5. Adequate bone marrow reserve and organ functions.\n6. Willing to comply with contraceptive restrictions.\n\nExclusion Criteria:\n\n1. Any of previous or current treatment prohibited by protocol.\n2. Any unresolved \\> grade 1 drug-related adverse events.\n3. Known or suspected Richter's transformation, or prolymphocytic leukemia.\n4. CNS involvement.\n5. Active infection.\n6. Any of severe cardiac or pulmonary abnormalities.\n7. Poorly controlled autoimmune anemia or autoimmune thrombocytopenia.\n8. Poorly controlled gastrointestinal disorder, inadequate absorption of medication or other systemic diseases.\n9. Prior malignancy within the past 3 years.\n10. Known allergy to study drugs, any of the ingredients of the study drugs, or xanthine oxidase inhibitors or rasburicase.","ALL","18 Years",{"count":19,"type":20},66,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL\u002FSLL.\n\nThis study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.",[26],"Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","RECRUITING","2026-06-18",{"date":30,"type":31},"2026-06-22","ACTUAL",{"date":33,"type":31},"2025-09-22",{"date":35,"type":20},"2030-01",{"name":37,"class":38},"Dizal Pharmaceuticals","INDUSTRY",15,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100603696","phase-3-a-study-of-dzd8586-versus-investigators-choice-in-rr-cllsll-tai-shan6-100603696","NCT07139873","A Study of DZD8586 Versus Investigator's Choice in r\u002Fr CLL\u002FSLL (TAI-SHAN6)","A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Inclusion Criteria:\n\n1. Male and female participants ≥ 18 years of age.\n2. ECOG performance status 0-2.\n3. Confirmed diagnosis of relapsed or refractory CLL\u002FSLL with indication for treatment.\n4. Adequate bone marrow reserve and organ system functions.\n5. Participants willing to comply with contraceptive restrictions.\n\nExclusion Criteria:\n\n1. Any unresolved \\> Grade 1 adverse event at the time of starting study treatment.\n2. Known or suspected Richter transformation.\n3. Known or suspected CNS involvement.\n4. Previous or current therapy and comedications meet exclusion criteria.\n5. Participants with major cardiovascular disease, active infection, malignancy or uncontrolled systemic disease.\n6. Nausea and vomiting not controlled or chronic gastrointestinal diseases, unable to swallow the formulated product or previous bowel resection that would preclude adequate absorption.\n7. Women who are breast feeding.\n8. History of hypersensitivity to active or inactive excipients of DZD8586 or drugs with a similar chemical structure or class.",{"count":48,"type":20},250,[50],"PHASE3","This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma who have progressed following prior therapy.\n\nPrimary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.",[26],"2026-05-31",{"date":55,"type":31},"2026-06-03",{"date":57,"type":31},"2025-09-08",{"date":59,"type":20},"2029-12",{"name":37,"class":38},2,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100557520","phase-2-dzd8586-in-patients-with-relapsed-or-refractory-cllsll-tai-shan8-100557520","NCT06539182","DZD8586 in Patients With Relapsed or Refractory CLL\u002FSLL (TAI-SHAN8)","A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Inclusion Criteria:\n\nParticipants who meet all the following criteria:\n\n1. Male and female ≥ 18 years of age.\n2. ECOG performance status 0-2.\n3. Confirmed diagnosis of CLL\u002FSLL with indication for treatment.\n4. Adequate bone marrow reserve and organ system functions.\n5. Willing to comply with contraceptive restrictions.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria:\n\n1. CNS involvement or Richter transformation.\n2. Stem cell transplantation, cell therapy, or gene therapy within 90 days. Approved small molecule therapy within 5 half-lives, monoclonal antibodies and antibody-drug conjugates within 28 days.\n3. Major surgery or significant traumatic injury within 4 weeks. Live attenuated vaccines or viral vector vaccines within 4 weeks.\n4. Take vitamin K antagonists or take more than 2 anticoagulants or antiplatelet drugs at the same time. Take proton pump inhibitors or strong CYP3A inhibitors or inducers.\n5. Active infection.\n6. Clinically significant cardiac disorders or abnormalities. History of thrombotic diseases, stroke or intracranial hemorrhage within 6 months.\n7. Nausea and vomiting not controlled or chronic gastrointestinal diseases, unable to swallow the formulated product or previous bowel resection that would preclude adequate absorption.\n8. Another malignancy within 2 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or non-melanomatous skin cancer.\n9. Women who are breast feeding.\n10. History of hypersensitivity to active or inactive excipients of DZD8586 or drugs with a similar chemical structure or class.",{"count":70,"type":20},155,[23],"This study will treat patients with CLL\u002FSLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.",[26],{"date":75,"type":31},"2026-06-02",{"date":77,"type":31},"2024-04-29",{"date":79,"type":20},"2028-03",{"name":37,"class":38},17,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":61},"100639384","phase-2-tafasitamab-with-acalabrutinib-and-venetoclax-for-the-treatment-of-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-100639384","NCT07582159","Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative.\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* Age: ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) ≤ 2\n* Histologically or flow cytometry confirmed diagnosis of B-CLL\u002FSLL as documented by medical records and with histology based on criteria established by the World Health Organization (WHO)\n* No prior treatment for CLL\u002FSLL, except steroids and\u002For rituximab to treat autoimmune complications\n* Active disease meeting criteria for requiring treatment per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines\n\n  * A minimum of any one of the following constitutional symptoms:\n\n    * Unintentional weight loss \\> 10% within the previous 6 months prior to screening.\n    * Extreme fatigue (unable to work or perform usual activities).\n    * Fevers of greater than 100.5°F for ≥ 2 weeks without evidence of infection.\n    * Night sweats without evidence of infection.\n  * Evidence of progressive marrow failure as manifested by the development of, or worsening of anemia or thrombocytopenia.\n  * Massive (i.e., \\> 6 cm below the left costal margin), progressive or symptomatic splenomegaly.\n  * Massive nodes or clusters (i.e., \\> 10 cm in longest diameter) or progressive lymphadenopathy.\n  * Progressive lymphocytosis with an increase of \\> 50% over a 2-month period, or an anticipated doubling time of less than 6 months.\n  * Autoimmune anemia or thrombocytopenia that is poorly responsive to corticosteroids.\n  * Symptomatic or functional extranodal involvement (eg, skin, kidney, lung, spine)\n* Participant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible\n* Absolute neutrophil count (ANC) ≥ 500\u002Fmm\\^3\n* Platelets ≥ 30,000\u002Fmm\\^3\n* Total bilirubin ≤ 2 X upper limit of normal (ULN) (unless has Gilbert's disease or compensated hemolysis directly attributable to CLL)\n* Aspartate aminotransferase (AST) ≤ 2.5 x ULN\n* Alanine aminotransferase ≤ 2.5 x ULN\n* Creatinine clearance of ≥ 30 mL\u002Fmin per 24 hour urine test or the Cockcroft-Gault formula\n* If not receiving anticoagulants: International Normalized Ratio (INR) OR Prothrombin (PT) ≤ 1.5 x ULN. If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants\n* If not receiving anticoagulants: Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN. If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants\n* If seropositive for HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV), nucleic acid quantitation must be performed. Viral load must be undetectable. HIV-infected patients on active anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential\\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study and after completion of study treatment as described below separately for males and females.\n\n  * Female participants must remain abstinent or use contraceptive methods with a failure rate of \\\u003C 1% per year during the treatment period and for at least 2 days after the final dose of acalabrutinib, 30 days after the last dose of venetoclax, and 3 months after the final dose of tafasitamab, whichever is longer. Women must refrain from donating eggs during this same period.\n\n    * Examples of contraceptive methods with a failure rate of \\\u003C 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n    * Hormonal contraceptive methods must be supplemented by a barrier method.\n  * For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agree to refrain from donating sperm, as defined below:\n\n    * With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\\u003C 1% per year during the treatment period and for at least 2 days after the final dose of acalabrutinib, 90 days after the last dose of venetoclax, and 3 months after the final dose of tafasitamab, whichever is longer. Male participants must refrain from donating sperm during this same period.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.\n  * A woman is considered of childbearing potential, ie, fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. Contraception methods include the following:\n\n    * Combined (estrogen- and progestogen- containing) hormonal contraception associated with the inhibition of ovulation\n\n      * Oral, intravaginal, or transdermal\n    * Progestogen-only hormonal contraception associated with the inhibition of ovulation\n\n      * Oral, injectable, implantable\n    * An intrauterine device\n    * Intrauterine hormone-releasing system\n    * Bilateral tubal occlusion Vasectomized partner (provided that the vasectomized partner is the sole sexual partner of the woman of childbearing potential study participant and that the vasectomized partner has received medical assessment of surgical success)\n    * Sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment, starting the day prior to first dose of study drug, for the duration of the study, and for ≥ 90 days after the last dose of zanubrutinib or ibrutinib. Total sexual abstinence should only be used as a contraceptive method if it is in line with the patients' usual and preferred lifestyle. Of note, barrier contraception (including male and female condoms with or without spermicide) is not considered a highly effective method of contraception, and, if used, this method must be used in combination with another acceptable method listed above. If patient is using hormonal contraceptives such as birth control pills or devices, a barrier method of contraception (eg, condoms) must also be used. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single follicle-stimulating hormone measurement is insufficient\n\nExclusion Criteria:\n\n* Chronic use of corticosteroids in excess of 20 mg\u002Fday prednisone or its equivalent\n* Major surgery (under general anesthesia) within 30 days prior to therapy\n* Uncontrolled coagulopathy or bleeding disorder. Direct oral anticoagulants are allowed\n* Use of moderate or strong cytochrome P450 3A4 (CYP3A4) inducer within 2 weeks of the first day of study therapy. CYP3A inhibitors are allowed\n* Exposure to vaccination with live vaccine within 30 days prior to cycle (C) 1 day (D) 1, or anticipated need for such vaccination during treatment\n* History of prior malignancy except:\n\n  * Malignancy treated with curative intent and no known active disease present for ≥ 2 years prior to initiation of therapy on current study;\n  * Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ) without evidence of disease\n  * Adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without evidence of disease;\n  * Asymptomatic prostate cancer managed with \"watch and wait\" strategy;\n* Uncontrolled immune hemolysis or thrombocytopenia (positive direct antiglobulin test in absence of hemolysis or history of immune-mediated cytopenias are not exclusions)\n* Active infection\n* Known positive test result for hepatitis C (HCV antibody serology testing) and a positive test result for HCV ribonucleic acid (RNA). Participants with positive serology are eligible in case of negative HCV RNA test results\n* Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Patients with past HBV infection (defined as negative hepatitis B surface antigen (HBsAg) and positive hepatitis B core antibody \\[HBcAb\\]) are eligible if HBV deoxyribonucleic acid (DNA) is undetectable. Patients who are positive for HCV antibody are eligible if polymerase chain reaction (PCR) is negative for HCV RNA\n* Known active human immunodeficiency virus (HIV) infection. Subjects who have an undetectable or unquantifiable HIV viral load with CD4 \\> 200 and are on highly active antiretroviral therapy (HAART) medication are allowed. Testing to be done only in patients suspected of having infections or exposures\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":90,"type":20},35,[23],"This phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)\u002Fsmall cell lymphoma (SLL). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tafasitamab is a monoclonal antibody that binds to CD19 antigen which is found on the surface of most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantle cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab with acalabrutinib and venetoclax may be safe and effective for treating patients with CLL\u002FSLL.",[94,26,95],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","NOT_YET_RECRUITING","2026-05-06",{"date":99,"type":31},"2026-05-12",{"date":101,"type":20},"2026-12-19",{"date":103,"type":20},"2029-04-14",{"name":105,"class":106},"City of Hope Medical Center","OTHER",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100582107","phase-1-zanubrutinib-in-combination-with-sonrotoclax-for-the-treatment-of-underrepresented-ethnic-and-racial-minorities-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-100582107","NCT06859008","Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","Feasibility of Treating Relapsed\u002FRefractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic\u002FRacial Minorities","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Age: ≥ 18 years on the day of signing the informed consent form\n* Eastern Cooperative Oncology Group (ECOG) ≤ 2\n* Patients are of the following self-identified racial\u002Fethnic groups:\n\n  * Cohort 1: Patients in any of the following categories:\n\n    * Black or African American\n    * Hispanic or Latino\n    * American Indian\u002FNative Alaskan\n    * Pacific Islander\u002FNative Hawaiian\n    * Any other patient that does not fit the definition of Cohort 2\n  * Cohort 2: Patients in either of following categories:\n\n    * Non-Hispanic White\n    * Non-Hispanic Asian\n* Confirmed diagnosis (per World Health Organization \\[WHO\\] guidelines, unless otherwise noted) of one of the following disease subtypes. Note that for disease subtypes that are known to respond to BTK inhibitor (BTKi) and\u002For BCL2 inhibitor (BCL2i) (e.g., marginal zone lymphoma \\[MZL\\], mantle cell lymphoma \\[MCL\\], CLL\u002FSLL), newly diagnosed or r\u002Fr patients are allowed\n\n  * Diffuse large B cell lymphoma (DLBCL)\n\n    * R\u002FR DLBCL (including all subtypes of DLBCL) defined as disease that relapsed after, or was refractory to, at least 2 prior lines of therapy. Patients should be considered by the investigator to be refractory to or not a candidate for approved therapies with proven efficacy including but not limited to chimeric antigen receptor (CAR) T cell therapy or bispecific antibody therapy\n    * Active disease requiring treatment\n  * Follicular lymphoma (FL)\n\n    * R\u002FR FL (grade 1, 2 or 3a based on WHO 2008 classification of tumors of hematopoietic and lymphoid tissue) and defined as disease that relapsed after, or was refractory to, at least 1 prior systemic therapy. Patients should be considered by the investigator for all approved therapies with proven efficacy including but not limited to CAR T cell therapy or bispecific antibody therapy\n    * Active disease requiring treatment\n  * Marginal zone lymphoma (MZL)\n\n    * R\u002FR extranodal, splenic, or nodal MZL defined as disease that relapsed after, or was refractory to, at least 1 prior therapy\n    * Active disease requiring treatment\n  * Mantle cell lymphoma (MCL)\n\n    * R\u002FR MCL defined as disease that relapsed after, or was refractory to, at least 1 prior systemic therapy\n    * Requiring treatment in the opinion of the investigator\n  * Chronic lymphocytic leukemia\u002Fsmall lymphocytic leukemia (CLL\u002FSLL)\n\n    * CLL\u002FSLL diagnosis that meets the International Workshop on CLL (International Workshop on Chronic Lymphocytic Leukemia \\[IWCLL\\]) criteria\n    * Patients with previously untreated and\u002For r\u002Fr CLL defined as disease that relapsed after, or was refractory to, at least 1 prior therapy will be included\n    * Patients must have an indication to start treatment\n* Measurable disease, defined as:\n\n  * CLL: at least 1 lymph node \\> 1.5 cm in longest diameter and measurable in 2 perpendicular dimensions by computed tomography (CT)\u002Fmagnetic resonance imaging (MRI) or clonal lymphocytes measured by flow cytometry\n  * DLBCL, FL, MZL, MCL, or SLL: at least 1 lymph node \\> 1.5 cm in longest diameter OR 1 extranodal lesion \\> 1.0 cm in the longest diameter, measurable in 2 perpendicular dimensions by CT\u002FMRI. For MZL, isolated splenomegaly is considered measurable for this study. For MCL, clonal lymphocytes measured by flow cytometry is considered measurable\n* Life expectancy of ≥ 6 months\n* Without bone marrow involvement: Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3\n\n  * NOTE: Growth factor is not permitted within 7 days of ANC assessment unless cytopenia is secondary to disease involvement\n* With bone marrow involvement: ANC ≥ 500\u002Fmm\\^3\n\n  * NOTE: Growth factor is not permitted within 7 days of ANC assessment unless cytopenia is secondary to disease involvement\n* Without bone marrow involvement: Platelets ≥ 75,000\u002Fmm\\^3\n\n  * NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment unless cytopenia is secondary to disease involvement\n* With bone marrow involvement: Platelets ≥ 30,000\u002Fmm\\^3\n\n  * NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Hemoglobin ≥ 7g\u002FdL\n\n  * NOTE: Red blood cell transfusions are not permitted within 7 days of hemoglobin assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease)\n* Aspartate aminotransferase (AST) ≤ 2.5 x ULN\n* Alanine aminotransferase (ALT) ≤ 2.5 x ULN\n* Creatinine clearance of ≥ 30 mL\u002Fmin per 24 hour urine test or the Cockcroft-Gault formula\n* Fridericia's formula-corrected QT interval (QTcF) ≤ 480 ms\n\n  * Note: Performed within 28 days prior to day 1 of protocol therapy\n* Seronegative for HIV antigen (Ag)\u002Fantibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative) OR\n\n  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable\n  * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* Meets other institutional and federal requirements for infectious disease titer requirements\n\n  * Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy\n* Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 90 days after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Major surgery ≤ 4 weeks of the first dose of study drug\n* Prior autologous stem cell transplant unless ≥ 30 days after transplant; or prior chimeric antigen receptor T cell (CAR-T) therapy unless ≥ 30 days after cell infusion\n* Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent\n* Prior therapy ≥ 2 months with or progression on a Bcl2 inhibitor (eg, venetoclax)\n* Vaccination or requirement for vaccination with a live vaccine within 35 days prior to the first dose of study drug or at any time during planned study treatment\n* Requires ongoing treatment with a strong CYP3A inducer\n* Requires ongoing treatment with warfarin or warfarin derivatives\n* Concurrent participation in another therapeutic clinical trial\n* Use of the following substances prior to the first dose of study drug:\n\n  * ≤ 28 days before first dose of study drug: Any biologic and\u002For immunologic-based therapy(ies) including experimental therapy(ies) for leukemia, lymphoma, or myeloma (including, but not limited to, monoclonal antibody therapy, eg, rituximab, and\u002For cancer vaccine therapy)\n  * ≤ 14 days before the first dose of study drug: systemic chemotherapy or radiation therapy\n  * ≤ 7 days before the first dose of study drug: corticosteroid given with antineoplastic intent other than control of BTK inhibitor withdrawal flare\n  * ≤ 5 half-lives before the first dose of study drug: BTK inhibitor, tyrosine kinase inhibitor, or other targeted small molecule given with antineoplastic intent\n* Known current central nervous system involvement by lymphoma\u002Fleukemia\n* Known plasma cell neoplasm, prolymphocytic leukemia, history of or currently suspected Richter's syndrome\n* Any uncontrolled or clinically significant cardiovascular disease including the following:\n\n  * Myocardial infarction (MI) within 6 months before screening\n  * NYHA (New York Heart Association) heart failure class III-IV\n  * Unstable angina within 3 months before screening\n  * History of clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)\n  * History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place\n* Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer\n* History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention\n* History of stroke or intracranial hemorrhage within 6 months before first dose of study drug\n* Severe or debilitating pulmonary disease\n* Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction\n* Active fungal, bacterial and\u002For viral infection requiring systemic therapy\n* Underlying medical conditions that, in the investigator's opinion, will render the administration of study drugs hazardous or obscure the interpretation of toxicity or adverse events (AEs)\n* Known active infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows:\n\n  * Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is undetectable (\\\u003C 20 IU), and if they are willing to undergo monitoring every 4 weeks for HBV reactivation\n  * Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody are eligible if HCV ribonucleic acid (RNA) is undetectable\n* Any condition which in the discretion of the investigator would compromise the ability to comply with study procedures\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents\n* Active and\u002For ongoing autoimmune anemia and\u002For autoimmune thrombocytopenia (e.g., idiopathic thrombocytopenia purpura)\n* Females only: Pregnant or breastfeeding\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":115,"type":20},37,[117],"PHASE1","This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Many racial and ethnic minorities face additional treatment challenges which may lead to poorer outcomes, however, there are fewer racial and ethnic minorities participating in clinical trials. Zanubrutinib, a type of tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Sonrotoclax works by blocking a protein called B-cell lymphoma-2 (Bcl-2). This protein helps certain types of blood cancer cells to survive and grow. When sonrotoclax blocks Bcl-2, it slows down or stops the growth of cancer cells and causes them to die. Zanubrutinib and sonrotoclax have been shown to be an effective treatment for B-cell cancers. Giving zanubrutinib in combination with sonrotoclax may be effective in treating ethnic and racial minorities with relapsed or refractory B-cell non-Hodgkin lymphoma.",[26,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137],"Recurrent Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3a Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Nodal Marginal Zone Lymphoma","Recurrent Splenic Marginal Zone Lymphoma","Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Refractory Grade 1 Follicular Lymphoma","Refractory Grade 2 Follicular Lymphoma","Refractory Grade 3a Follicular Lymphoma","Refractory Mantle Cell Lymphoma","Refractory Nodal Marginal Zone Lymphoma","Refractory Splenic Marginal Zone Lymphoma","2026-04-16",{"date":140,"type":31},"2026-04-20",{"date":142,"type":31},"2025-08-25",{"date":144,"type":20},"2029-01-31",{"name":105,"class":106},1,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":167,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":181,"locationsCount":183},"100461905","phase-1-treatment-of-chinese-participants-with-b-cell-malignancies-with-bgb-16673-a-bruton-tyrosine-kinase-targeted-protein-degrader-100461905","NCT05294731","Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","A Phase 1\u002F2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies","Key Inclusion Criteria\n\n1. Provision of signed and dated written informed consent prior to any study\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2\n3. Adequate organ function of coagulation function, liver function, renal function and pancreatic function and measure disease per disease-specific response criteria\n4. Phase 1: Confirmed diagnosis of R\u002FR Marginal Zone Lymphoma (MZL), Follicular Lymphoma (grade 1-3a), Waldenström Macroglobulinemia (WM), non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), Richter's transformation to DLBCL, MCL, or CLL\u002FSLL\n5. Phase 2: Confirmed diagnosis of MCL, or CLL\u002FSLL\n6. Highly effective method of birth control during study treatment period, and for at least 90 days after the last dose of the study drug\n\nKey Exclusion Criteria\n\n1. Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer\n2. Require ongoing systemic treatment for any other malignancy or systemic corticosteroid treatment\n3. Receiving treatment with a strong CYP3A inhibitor or inducer ≤ 14 days before the first dose of BGB-16673, or proton-pump inhibitors ≤ 5 days before the first dose of BGB-16673.\n4. Current or history of central nervous involvement\n5. Prior autologous stem cell transplant unless ≥ 3 months after transplant, prior chimeric cell therapy unless ≥ 6 months after cell infusion, prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply",{"count":155,"type":20},146,[117,23],"This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts",[159,160,161,26,162,163,164,165,166],"B-cell Malignancy","Non-Hodgkin Lymphoma","Mantle Cell Lymphoma","Waldenström Macroglobulinemia","Marginal Zone Lymphoma","Follicular Lymphoma","DLBCL Unclassifiable","Richter's Transformation",[159,168,169,170,166,171,172,173,174],"MZL","FL","DLBCL","CDAC","BTK","degrader","BGB-16673","2026-04-14",{"date":177,"type":31},"2026-04-17",{"date":179,"type":31},"2022-05-06",{"date":144,"type":20},{"name":182,"class":38},"BeiGene",29,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":191,"sex":16,"minAge":17,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":61},"100506633","the-effects-of-exercise-on-immune-phenotype-of-indolent-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia-patients-100506633","NCT05876923","The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients","The Effects of Acute and Chronic Exercise on the Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients","Inclusion Criteria:\n\n* English speaking\n* Between the ages of 18-80\n* Histologically confirmed diagnosis of indolent non-Hodgkin lymphoma (NHL) will be required to participate in Aim 2 (CLL\u002FSLL only), aim 3 and 4 (indolent NHL) and aim 5 (indolent NHL) of this study\n\nExclusion Criteria:\n\n* Healthy subjects participating in Aim 1 will be excluded if they have known cardiovascular or pulmonary disease (e.g. heart disease, coronary artery disease, chronic obstructive pulmonary disease \\[COPD\\], asthma, etc.) an orthopedic or musculoskeletal limitation which would limit ability to exercise or are a current or former smoker\n* Indolent NHL individuals receiving treatment must have least 8 weeks of planned treatment remaining and those who have already received treatment must be at least 6 months post and have no planned treatments during the 12-week intervention period to be eligible. Individuals that are participating prior to receiving treatment must not have any scheduled treatments during their participation. Individuals will be excluded if they have uncontrolled hypertension, cardiac illness, or are not approved by their oncologist to participate",true,"80 Years",{"count":194,"type":20},70,[196],"NA","This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers. Increasing CLL patients overall physical fitness levels, through exercise during the observation stage, may provide a realistic approach means to increase survival, decrease treatment-related side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be used to strengthen the immune system of indolent NHL and CLL patients, delay time to disease progression, assess the need for treatment, and assess infection rates.",[26,199],"Indolent Non-hodgkin Lymphoma","2026-04-06",{"date":202,"type":31},"2026-04-09",{"date":204,"type":31},"2023-06-12",{"date":206,"type":20},"2028-04",{"name":208,"class":106},"Mayo Clinic",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":146},"100574312","phase-2-acalabrutinib-for-the-treatment-of-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-100574312","NCT06757647","Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Prospective Phase 2 Study of the Effect of Acalabrutinib on Myocardium on Ibrutinib Exposed Patients With CLL","Inclusion Criteria:\n\n* Men and women \\>= 18 years of age\n* Diagnosis of CLL\u002FSLL meeting criteria as defined by International Workshop on Chronic Lymphocytic Leukemia (iWCLL) 2018 criteria\n* CLL patients cardiac intolerant to current treatment with ibrutinib as defined by AF or other cardiac arrhythmias. Other ibrutinib-related intolerances will be excluded\n* Eastern Cooperative Oncology Group (ECOG) performance status of =\\\u003C 2\n* Absolute neutrophil count (ANC) \\>= 1000\u002Fmm\\^3 (Independent of growth factor support at screening unless due to marrow involvement by CLL\u002FSLL and\u002For disease-related immune thrombocytopenia. If cytopenias are due to disease in the bone marrow any degree of cytopenias is allowed. Patients with active uncontrolled autoimmune cytopenias are excluded)\n* Platelets \\>= 30,000\u002Fmm\\^3 (Independent of growth factor support at screening unless due to marrow involvement by CLL\u002FSLL and\u002For disease-related immune thrombocytopenia. If cytopenias are due to disease in the bone marrow any degree of cytopenias is allowed. Patients with active uncontrolled autoimmune cytopenias are excluded)\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) (excepting Gilbert's syndrome) (at screening)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (at screening)\n* Creatinine clearance \\>= 30 mL\u002Fmin\u002F1.73m\\^2 (at screening)\n\n  * Using 24-hour creatinine clearance or modified Cockcroft-Gault equation\n* Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for 2 days after the last dose of acalabrutinib\n* Willing and able to participate in all required evaluations and procedures in this study protocol\n* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information\n\nExclusion Criteria:\n\n* Prior exposure to acalabrutinib for primary cohort and prior exposure to BTK inhibitor for pilot cohort\n* Presence of C481S mutation or PCLG2 mutation\n* Disease progression on ibrutinib\n* History of prior malignancy that could affect compliance with the protocol or interpretation of results, except for the following:\n\n  * Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the prostate at any time prior to study\n  * Other cancers not specified above that have been curatively treated by surgery and\u002For radiation therapy from which subject is disease-free for \\>= 3 years without further treatment\n* Clinically significant cardiovascular disease such as prior myocarditis, congestive heart failure, prior documented myocardial infarction (i.e., not self-reported), known infiltrative cardiomyopathy (ex. cardiac sarcoidosis, cardiac amyloidosis, etc.) or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. Note: Subjects with controlled, asymptomatic atrial fibrillation can enroll on study\n* Prior allogeneic stem cell transplantation\n* Prior cardiac transplantation\n* Systemic or non-cancer targeted anti-inflammatory medications (i.e., steroids)\n* Contradictions to MRI: non-compatible metal implant, weight \\> 300 pounds (lbs.) (MRI scanner limit), severe claustrophobia, advanced or end-stage renal disease (ESRD) (contraindication to gadolinium), pregnancy, cognitive disabilities that may impair ability to comply with instructions or provide informed consent\n* Has difficulty with or is unable to swallow oral medication or has significant. gastrointestinal disease that would limit absorption of oral medication\n* Known history of infection with HIV or any active significant infection (e.g., bacterial, viral, or fungal) including subjects with positive cytomegalovirus \\[CMV\\] deoxyribonucleic acid \\[DNA\\] polymerase chain reaction \\[PCR\\])\n* Known history of hypersensitivity or anaphylaxis to study drug(s) including active product or excipient components\n* Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease)\n* Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura)\n* Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening\n* Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor\u002Finducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited\n* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists\n* Prothrombin time (PT)\u002Finternational normalized ratio (INR) or activated partial thromboplastin time (aPTT) (in the absence of lupus anticoagulant) \\> 2 x ULN\n* Requires treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Note: Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study\n* History of significant cerebrovascular disease\u002Fevent, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug\n* Major surgical procedure within 28 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and\u002For complications from the intervention before the first dose of study drug\n* Received a live virus vaccination within 28 days of first dose of study drug\n* History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)\n* Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug\n* Hepatitis B or C serologic status:\n\n  * Subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative polymerase chain reaction (PCR) and must be willing to undergo DNA PCR testing during the study to be eligible. Those who are HBsAg positive or hepatitis B PCR positive will be excluded\n  * Subjects who are hepatitis C antibody positive will need to have a negative PCR result to be eligible. Those who are hepatitis C PCR positive will be excluded\n* Breastfeeding or pregnant\n* Concurrent participation in another therapeutic clinical trial",{"count":217,"type":20},61,[23],"This phase II trial tests how well acalabrutinib works in treating patients with chronic lymphocytic leukemia (CLL)\u002Fsmall lymphocytic lymphoma (SLL) and evaluates how treatment with acalabrutinib affects heart function. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. CLL\u002FSLL patients treated with a different BTK inhibitor called ibrutinib often experience cardiac side effects, leading to discontinuation of life-saving therapy. Treatment with acalabrutinib after discontinuing, or even before starting, treatment with ibrutinib may reverse or prevent cardiac side effects and be an effective treatment option for patients with CLL\u002FSLL.",[26],"2025-12-10",{"date":223,"type":31},"2025-12-16",{"date":225,"type":31},"2025-05-27",{"date":227,"type":20},"2027-12-31",{"name":229,"class":106},"Seema Bhat",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":21,"phases":239,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":146},"100488678","implanted-loop-recorders-for-detection-and-management-of-arrhythmia-with-bruton-tyrosine-kinase-inhibitors-100488678","NCT05643235","Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors","Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors","Inclusion Criteria:\n\n* \\>18yo\n* Willing to sign and date consent form,\n* Willing to be remotely monitored\n* Initiating BTK inhibitor for approved condition (i.e. CLL, Waldenstrom's, etc)\n* Willing to have Medtronic cardiac monitor inserted to allow at minimum 24 hours continuous monitoring prior to initiating BTK inhibitor\n\nExclusion Criteria:\n\n* Documented AF\u002FVA in past 12 months\n* Cerebral Vascular Accident (CVA) or Transient Ischemic Attack (TIA) in past year\n* Has current implanted pulse generator, defibrillator, pacemaker, or resynchronization device\n* heart surgery within past 90 days\n* Myocardial Infarction within past 90 days\n* Patient is taking an anti-arrhythmic or anticoagulant\n* has concomitant condition that precludes safe participation in study (substance abuse, etc)\n* Enrollment in separate study that could confound results of this study",{"count":238,"type":20},50,[196],"This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.",[242,243,244,94,26],"Atrial Fibrillation","Supraventricular Arrhythmia","Ventricular Arrhythmias and Cardiac Arrest",[246,247,161,248,249,250,251,252,253,254,255,256],"Bruton tyrosine kinase (BTK)","Chronic Lymphocytic Leukemia (CLL)","Waldenstrom's macroglobulinemia","atrial fibrillation (AF)","ventricular arrhythmia (VA)","sudden cardiac death","ibrutinib","acalabrutinib","zanubrutinib","pirtobrutinib","Implanted Loop Recorder\u002FImplanted Cardiac Monitor (ILR)","2025-09-12",{"date":259,"type":31},"2025-09-18",{"date":261,"type":31},"2023-01-01",{"date":263,"type":20},"2030-12-01",{"name":265,"class":106},"Northwell Health",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":146},"100591258","phase-2-lp-168-and-obinutuzumab-for-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-cllsll-and-variants-of-this-100591258","NCT06978088","LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) and Variants of This","A Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) and Variants of This","Inclusion Criteria:\n\n1. Diagnosis of CLL or SLL meeting criteria established in the 2018 iwCLL criteria and requiring treatment. Patients with variation in flow cytometry findings will be allowed to enroll if cytogenetics and\u002For mutational studies are supportive of CLL\u002FSLL variant.\n\n   a) Note: Variation in flow cytometry is defined as patients who have atypical immunophenotyping for CLL (CD5 negative, CD23 negative or surface expression of CD79b that is bright ) but clinically behave like CLL (leukocytosis, lymphadenopathy and splenomegaly) and have the FISH\u002FCytogenetics translocations(del 13q, trisomy 12, Del11q) or genomic features (XPO1, NOTCH1, SF3B1, FBXW7, MYD88, BIRC3, TRAF3, NFKBIE, SAMHD1, POT1, HIST1H1E, CHD2, ZMYM3, EGR2 and others) that are suggestive of CLL.\n2. Meet the criteria for inclusion into at least one of the following 2 cohorts:\n\n   1. Cohort 1: One or more prior therapies for CLL\u002FSLL including BCL2 inhibitor (BCL2i), and\u002For chemotherapy and\u002For BTK inhibitor (BTKi).\n\n      • Note: Patients can be eligible if their CLL\u002FSLL has been non-responsive to a covalent and noncovalent BTKi. Patients intolerant to BTKi whose disease becomes resistant to a second one are eligible to enroll. Prior treatment with CD20 will not be exclusionary.\n   2. Cohort 2: Treatment with a prior BTKi (covalent and noncovalent) and have a BTK gatekeeper mutation in the T474 coordinate.\n3. Age ≥18 years.\n4. ECOG performance status ≤2 (or Karnofsky ≥60%, see Appendix A).\n5. Patients must have adequate organ and marrow function as defined below:\n\n   1. ANC ≥1,000\u002FmcL, unless if neutropenia is due to underlying CLL bone marrow disease.\n   2. Platelets ≥ 50,000\u002F µL unless if thrombocytopenia is due to underlying CLL bone marrow disease then platelets of ≥20,000 is acceptable\n   3. Total bilirubin ≤1.5 x ULN (excepting Gilbert's syndrome, who may have a bilirubin \\> 1.5 × ULN, per discussion between the Investigator and the UC PI).\n   4. AST and ALT ≤2.5 × ULN.\n   5. Estimated glomerular filtration rate (by Modification of Diet in Renal Disease \\[MDRD\\]) or Chronic Kidney Disease Epidemiology \\[CKD-EPI\\]) ≥ 30 mL\u002Fmin\n6. Women of childbearing potential and non-sterile males must practice at least 1 of the following methods of birth control with their partner(s) throughout the study and for 30 days after discontinuing study drug:\n\n   1. Total abstinence from sexual intercourse as the preferred lifestyle of the patient; periodic abstinence is not acceptable.\n   2. Surgically sterile partner(s) by vasectomy, bilateral orchiectomy, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.\n   3. Intrauterine device.\n   4. Hormonal contraceptives (oral, parenteral, vaginal ring or transdermal) for at least 1-month prior to study drug administration.\n7. Women of childbearing potential must have a negative pregnancy result as follows: At Screening on a serum sample obtained within 7 days prior to the first study drug administration. If a urine pregnancy test at any timepoint during the study is positive or indeterminate, a serum pregnancy test will be performed for confirmation.\n8. Non-sterile males must refrain from sperm donation, from initial study drug administration until 30 days after the last dose of study drug.\n9. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. Patients with active Richter's transformation.\n2. Patient has received any of the following therapies within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug, or has not recovered to ≤ Grade 1 clinically significant adverse effect(s)\u002Ftoxicity(s) of the previous therapy (other than alopecia):\n\n   1. Any anti-cancer therapy including chemotherapy, biologic or immunotherapy, radiotherapy, etc.\n   2. Any investigational therapy, including targeted small molecule agents.\n   3. For patients who come off BCR antagonist treatment (BTK inhibitors, PI3K inhibitors, etc.), allow washout for 5 half-lives as these patients progress quickly after treatment discontinuation and then remain eligible (steroids may be given during the washout to allow for disease control, see d below for details).\n   4. When a patient's intercurrent health condition would require short term steroid use this should be discussed with the Investigator in consultation with the Medical Monitor. Steroids are allowed for disease control in those R\u002FR patients when use is limited to 2-3 days to allow for control of the underlying disease. Steroids may be given during the washout to allow for disease control.\n3. Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous, in the opinion of the Investigator.\n4. Patients who require anti-coagulation with warfarin or equivalent Vitamin K antagonist.\n5. Major surgery within 14 days prior to the first dose of study drug.\n6. Patients who have received the following medications or therapies within 5 half-lives or 14 days, whichever is shorter, prior to the first dose of study drug:\n\n   1. Steroid therapy (at dosages equivalent to prednisone \\>20 mg\u002Fday) for anti- neoplastic intent (except as noted in exclusion criterion #2).\n   2. Cytochrome P450, family 3, subfamily A (CYP3A4) strong inhibitors and strong CYP2C8 inducers\u002Finhibitors (see the list in Appendix B)\n   3. Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort (Appendix B)\n   4. There is a 28-day washout period required for patients who have had prior CAR T treatment if there is no evidence of cytokine release syndrome (CRS) or other AEs related to the CAR T treatment per discussion with the UC PI; reduced washout period may be acceptable after discussion with UC PI.\n   5. Drugs that are substrates of MATE1 and MATE2-K should be avoided or substituted for other medications if possible. Use of these (if done) must be discussed with the PI of the study. (Appendix D).\n7. Patient has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or Star fruit within 3 days prior to the first dose of study drug.\n8. Patient requires treatment with systemic acid-reducing agents, H2 blocking agent and proton pump inhibitors, with the following exceptions:\n\n   1. Proton pump inhibitors should be discontinued at least 7 days or at least 5-half-lives (whichever is shorter) prior and held throughout the study.\n   2. If concurrent use of an H2 blocking agent is necessary, it must be administered only between 2 and 3 hours after the dose of LP-168. If not taken during this time, the dose of H2 blocking agents should not be taken again until 2 - 3 hours after the next dose of LP-168.\n   3. If concurrent use of a local antacid is necessary, it must be administered 2 or more hours before and\u002For 2 or more hours after the dose of LP-168.\n9. Patient has clinically significant screening electrocardiogram (ECG) abnormalities including:\n\n   1. 2nd degree AV block type II, 3rd degree block, Grade 2 or higher bradycardia, and corrected QT interval (QTcF) ≥ 480ms (calculated per Fridericia's formula \\[QTcF = QT\u002FRR (1\u002F3)\\]).\n   2. For patients with presence of right bundle branch block (RBBB) or left bundle branch block (LBBB), cardiology review is needed to correct QTcF calculation using Sponsor recommended formula (Simplified Formula for Bundle Branch Block). See Appendix C.\n   3. Other clinically significant ECG abnormalities per PI discretion.\n10. Patient has significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 180 days prior to the first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification or left ventricular ejection fraction ≤ 40%.\n11. Patient has a history of stroke or intracranial hemorrhage within 180 days prior to the first dose of study drug.\n12. Patients who have undergone autologous\u002Fallogeneic hematopoietic stem cell transplantation (HSCT) therapy within 60 days of the first dose of LP-168, or patients on immunosuppressive therapy post-HSCT at the time of Screening, or currently with clinically significant graft-versus-host disease (GVHD) as per treating physician (patients in relapse after allogeneic transplantation must be off treatment with systemic immunosuppressive agents for at least 4 weeks). The use of topical steroids and\u002For up to 20 mg\u002Fday prednisone or equivalent systemic steroids for ongoing GVHD is permitted.\n13. Pregnant women, those planning to become pregnant during the study, and\u002For breastfeeding women are ineligible for participation.\n14. Patients with known malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.\n15. Known hypersensitivity to any of the components of LP-168 (see Investigators Brochure for a list of components).\n16. Patients with active bleeding disorder.\n\n    a) NOTE: Von Willebrand's disease or hemophilia will not be excluded if patient is on treatment and well controlled.\n17. Patient exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:\n\n    1. Uncontrolled active systemic infection (bacterial, fungal, viral);\n    2. Known poorly controlled (defined as less than 200 CD4 count) human immunodeficiency virus (HIV) or active hepatitis B or C infection (active hepatitis B defined as HBsAg positive, or HBcAb positive with detectable HBV DNA load; active hepatitis C defined as HCV antibody positive with HCV RNA positive)\n    3. Unexplained fever \\> 38.3°C within 7 days prior to the first dose of study drug administration (if the fever is considered attributed to the patient's malignancy or an explained infection, the Patient may be enrolled at the discretion of the Investigator).\n18. Patient has a history of other active malignancies within the past 1 year prior to study entry, with the exception of:\n\n    1. Breast cancer or prostate cancer on endocrine therapy with stable disease.\n    2. Continuation of maintenance therapy in patients with adequately treated malignancy.\n    3. Cancer with expected survival of 2 years or more or that will not confound evaluation of LP-168 treatment.\n    4. Adequately treated in situ carcinoma of the cervix uteri.\n    5. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin.\n    6. Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.\n    7. Patients with active CNS involvement can be enrolled per Investigator discretion; patients with significant clinical symptoms, including any that require treatment with high dose steroid, will be excluded.",{"count":274,"type":20},34,[23],"Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) and Variants of This.",[26,95,278,94],"CLL\u002FSLL",[280,281,94,95],"LP-168","Obinutuzumab","2025-08-11",{"date":284,"type":31},"2025-08-14",{"date":286,"type":31},"2025-06-01",{"date":288,"type":20},"2034-06-01",{"name":290,"class":106},"Zulfa Omer",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":300,"phases":4,"briefSummary":301,"conditions":302,"keywords":306,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":4},"100510212","chantreal-world-study-of-duvelisib-in-the-treatment-of-non-hodgkins-lymphoma-nhl-100510212","NCT05923502","(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)","(CHANT)A Prospective, Multicenter, Non-interventionistic Real-world Study of Duvelisib Capsules in the Treatment of Non-Hodgkin's Lymphoma (NHL).","Inclusion Criteria:\n\n* To participate in the study voluntarily and sign the informed consent (ICF), with good compliance and cooperative visits;\n* Patients must be ≥ 18 years of age (Based on the date of signing the informed Consent (ICF));\n* Pathologically or Histologically confirmed NHL including but not limited to the following subtypes:\n\n  1. Follicular lymphoma (FL);\n  2. Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma or Richter syndrome (CLL\u002FSLL or RS);\n  3. Marginal zone lymphoma (MZL);\n  4. Peripheral T-cell lymphoma (PTCL);\n  5. Diffuse large B-cell lymphoma (DLBCL).\n* Patients who have received at least one systemic chemotherapy and have relapsed at the end of the treatment or progressed during treatment;\n* Must have adequate organ function defined by the following laboratory parameters:\n\n  1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 0.5 × 10\\^9\u002FL, Platelet count (PLT) ≥ 25 × 10\\^9\u002FL, blood transfusion can be used before medication;\n  2. Liver and kidney function: Aspartate transaminase (AST) and alanine aminotransferase (ALT)≤5.0 × ULN;\n  3. Estimated creatinine clearance value ≥30 milliliters\u002Fminute (as determined by the Cockcroft-Gault method).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n* Patients with infections should be treated first and then considered for enrollment when the infection is under control.\n\nExclusion Criteria:\n\n* Female subjects who are pregnant or breastfeeding;\n* Estimated lifetime is less than 3 months;\n* In the investigator's judgment, patients who require but are unable to receive prophylactic treatment for Pneumocystis or herpes simplex virus (HSV) prior to trial drug treatment;\n* History or concurrent condition of interstitial lung disease of any severity and\u002For severely impaired lung function;\n* Prior history of drug-induced colitis or drug-induced interstitial pneumonia;\n* Known hypersensitivity to Duvelisib or its excipients;\n* Administration of medications or foods that are strong inhibitors or inducers of CYP3A beginning 2 weeks prior to the first dose of Duvelisib;\n* According to the judgement of the researcher, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of the study.",{"count":299,"type":20},200,"OBSERVATIONAL","This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.",[164,26,303,163,304,305],"Richter Syndrome","Peripheral T Cell Lymphoma","Diffuse Large B Cell Lymphoma",[307],"NHL; Duvelisib","2023-10-18",{"date":310,"type":31},"2023-10-23",{"date":312,"type":20},"2023-10-20",{"date":314,"type":20},"2027-11-30",{"name":316,"class":106},"Ruijin Hospital"]